"Hims & Hers rose like a rocket during the telehealth boom. What began as a platform for hair-loss treatments, erectile dysfunction meds, and skincare evolved into a weight-loss powerhouse once GLP-1 agonists exploded in popularity. During the acute shortage of Wegovy and Ozempic in 2023-2024, Hims capitalized by offering compounded semaglutide versions at lower prices and faster delivery."
"Last April's partnership to expand Wegovy access via telehealth lasted only until June, when Novo abruptly terminated the deal, citing safety concerns over Hims' compounded products. The real hammer came last month: Novo sued for patent infringement after Hims launched a $49 compounded oral pill mimicking Novo's new formulation."
"Novo Nordisk, which sued the telehealth provider just last month over copycat compounded GLP-1 drugs, has now agreed to partner with Hims to sell its branded obesity medications - including Wegovy and Ozempic - directly through the platform. The deal is expected to be announced as soon as Monday, ending the bitter legal feud."
Hims & Hers experienced rapid growth during the telehealth boom by offering compounded semaglutide at lower prices during the 2023-2024 shortage of Wegovy and Ozempic. However, the company faced a dramatic reversal when Novo Nordisk terminated their partnership in June, citing safety concerns about compounded products, and subsequently sued for patent infringement over a $49 compounded oral pill. This legal conflict, combined with regulatory pressures, severely damaged Hims' business. The unexpected reversal came when Novo Nordisk agreed to partner with Hims to sell its branded obesity medications directly through the platform, ending the feud and restoring a critical revenue stream. Hims shares surged approximately 40% following the announcement.
#glp-1-medications #telehealth-partnerships #patent-litigation #obesity-drug-market #business-turnaround
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]